Previous study conducted by Nakajima and colleagues reported that pemafibrate significantly improved serum ALT, γ-GTP and ALP levels in patients with non-alcoholic fatty liver disease (NAFLD), compared with placebo (65). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.